ARRAY BIOPHARMA INC. FIRST AMENDMENT TO SUBORDINATED CONVERTIBLE PROMISSORY NOTESSubordinated Convertible Promissory Notes • August 9th, 2017 • Array Biopharma Inc • Pharmaceutical preparations
Contract Type FiledAugust 9th, 2017 Company IndustryThis First Amendment to Subordinated Convertible Promissory Notes (this “Amendment”) is entered into as of August 7, 2017 by and among Array BioPharma Inc., a Delaware corporation (the “Company”), Redmile Biopharma Investments I, L.P. (“Biopharma I”) and Redmile Capital Offshore Fund II, Ltd. (“Offshore II”, together with Biopharma I, the “Noteholders”).